Search Results - Elisabeth André-Garnier
- Showing 1 - 3 results of 3
-
1
An NS5A single optimized method to determine genotype, subtype and resistance profiles of Hepatitis C strains. by Elisabeth Andre-Garnier, Bernard Besse, Audrey Rodallec, Olivier Ribeyrol, Virginie Ferre, Caroline Luco, Laura Le Guen, Nathalie Bourgeois, Jérôme Gournay, Eric Billaud, François Raffi, Marianne Coste-Burel, Berthe-Marie Imbert-Marcille
Published 2017-01-01
Article -
2
Raltegravir 1200 mg once daily as maintenance therapy in virologically suppressed HIV-1 infected adults: QDISS open-label trial by Nolwenn Hall, Clotilde Allavena, Christine Katlama, Alexandra Jobert, Jean-Michel Molina, Eric Cua, Firouzé Bani-Sadr, Laurent Hocqueloux, Claudine Duvivier, Dominique Merrien, Hitoto Hikombo, Elisabeth André-Garnier, Aurélie Gaultier, François Raffi, the QDISS Study Group
Published 2022-01-01
Article -
3
Natural non-homologous recombination led to the emergence of a duplicated V3-NS5A region in HCV-1b strains associated with hepatocellular carcinoma. by Hélène Le Guillou-Guillemette, Adeline Pivert, Elise Bouthry, Cécile Henquell, Odile Petsaris, Alexandra Ducancelle, Pascal Veillon, Sophie Vallet, Sophie Alain, Vincent Thibault, Florence Abravanel, Arielle A Rosenberg, Elisabeth André-Garnier, Jean-Baptiste Bour, Yazid Baazia, Pascale Trimoulet, Patrice André, Catherine Gaudy-Graffin, Dominique Bettinger, Sylvie Larrat, Anne Signori-Schmuck, Hénia Saoudin, Bruno Pozzetto, Gisèle Lagathu, Sophie Minjolle-Cha, Françoise Stoll-Keller, Jean-Michel Pawlotsky, Jacques Izopet, Christopher Payan, Françoise Lunel-Fabiani, Christophe Lemaire
Published 2017-01-01
Article